Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28055976 | 0.85 | IDO1 (0.50) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL943888 | 0.74 | IDO1 (0.50) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2090624 | 0.72 | IDO1 (0.48) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2091029 | 0.71 | MAOB (0.48) | TAAR1IDO1MAOBLMNACYP2A6 | |
| SCHEMBL12121938 | 0.70 | IDO1 (0.46) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11478072 | 0.70 | IDO1 (0.46) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL16775681 | 0.70 | IDO1 (0.46) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9667523 | 0.70 | TAAR1 (0.71) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13435556 | 0.70 | TAAR1 (0.41) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28930416 | 0.70 | CTBP2 (0.41) | TAAR1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090253662-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090192128-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM | NITROMED INC. (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1943361-A4 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20090075956-A1 | Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3 | NITROMED, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2007019448-A2 | NITRIC OXIDE ENHANCING ANGIOTENSIN II ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007016136-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016677-A2 | NITRIC OXIDE ENHANCING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006127591-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006110601-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF NOS3 | NITROMED, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006102071-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099416-A1 | 2-METHYL INDOLE CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006093864-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006078995-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUP COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | TAAR1 1292/4885HTR3E 1205/4885HTR3B 1563/4885 |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | TAAR1 1664/4885HTR3E 908/4885HTR3B 919/4885 |
| US-20090192128-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM | ADRB3, ADRB1, EDNRB | TAAR1 1710/4885HTR3E 1385/4885HTR3B 1864/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | TAAR1 920/4885HTR3E 898/4885HTR3B 923/4885 |
| US-20090075956-A1 | Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3 | NOS3, NOS2, TNNI3 | TAAR1 4025/4885HTR3E 1821/4885HTR3B 2498/4885 |
| US-20090253662-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | HSD11B2, HSD11B1, CYP11B2 | TAAR1 4183/4885HTR3E 3281/4885HTR3B 2867/4885 |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NOS1, NOS2, NOS3 | TAAR1 1759/4885HTR3E 2695/4885HTR3B 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.